Conference Documentation: Immunogenicity

Day 1

8:30

Registration & Coffee

9:00

Chair's Opening Remarks

Guilhem Richard, Computational Immunologist, EpiVax Inc

9:10

How to switch off unwanted immune responses

David Wraith, Chief Scientific Officer and Founder, Apitope International NV

9:50

Synthetic Vaccine Particles (SVPs) for the prevention of anti-drug antibodies

Kei Kishimoto , Chief Scientific Officer, Selecta Biosciences

10:30

Morning Coffee

11:00

Achieving immunological tolerance – are we there yet?

Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB

11:40

Evaluation of the immunogenicity of orally administered recombinant human BSSL in a phase III clinical study in pre-term infants

Margareta Wiken, Bioanalytical Manager, Swedish Orphan Biovitrum

12:20

Networking Lunch

13:20

Early immunogenicity assessment of biotherapeutics: a decade at a glance

Sofie Pattijn, Chief Technology Officer, ImmunXperts

14:00

Predicting T cell immunogenicity; Moving beyond MHC binding

Morten Nielsen, Associate Professor, The Technical University Of Denmark

14:40

Afternoon Tea

15:20

Immune tolerant mice as the model for studying immunogenicity?

Grzegorz Kijanka, Postdoctoral Researcher , Leiden Academic Centre for Drug Research, Leiden University

16:00

Validation of cell based antibody neutralisation assays

Bassam Hallis, Head of Pre-Clinical Development, Public Health England

16:40

Mission Impossible? Tweaking Bridging ELISA to Achieve Required Drug Tolerance for ADA Detection of Therapeutic Antibodies

Linglong Zou, Director of Experimental Immunology, Teva Pharmaceuticals

17:20

Chair’s Closing Remarks and Close of Day One

Guilhem Richard, Computational Immunologist, EpiVax Inc

Day 2

8:30

Registration & Coffee

9:00

Chair's Opening Remarks

Sandra Garces, Rheumatologist Consultant and Researcher , Garcia de Orta’s Hospital

9:10

Predicting Immunogenicity in the Era of Personalized Medicine: A Need for Individual Risk Assessment

Guilhem Richard, Computational Immunologist, EpiVax Inc

9:50

Drug Immunogenicity: What have we learned from the use of biologics in clinical practice?

Sandra Garces, Rheumatologist Consultant and Researcher , Garcia de Orta’s Hospital

10:30

Morning Coffee

11:00

RG7787 - The coming of age of immunotoxins for solid tumour therapy. Are we there yet?

Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development , Roche Innovation Center Penzberg

11:40

Immunogenicity prediction and assessment of nanobodies

Chloe Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels

12:20

Networking Lunch

13:20

Peptide immunotherapy for the treatment of autoimmune disease – closer to a cure?

Emma Smith, Senior Group Leader, UCB

14:00

ABIRISK: using immunological signatures to predict immunogenicity

Marsilio Adriani, Postdoctoral Research Associate, University College London

14:40

Afternoon Tea

15:20

The two main outcomes of T cell amplification assays for immunogenicity prediction: T cell repertoire and epitopes

Bernard Maillere, Research Director and Head, Immunology Laboratory, Institute of Biology and Technologies

16:00

An integrated approach to managing immunogenicity risk and drug immune modulation

Jeremy Fry, Assay Specialist , ProImmune Ltd.

16:40

Chair's Closing Remarks and Close of Day Two

Sandra Garces, Rheumatologist Consultant and Researcher , Garcia de Orta’s Hospital

Understanding immunogenicity is a key challenge in the development of therapeutics with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity. This conference explores the latest updates on the prediction and reduction of immunogenicity, clinical results and interpetations and optimising bioassays.

Led by selected case studies from leading drug developement teams, bioanalytical experts, and academics we aim to provide the insights and sharing necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.